SEC Company Response from Oncocyte Corp (OCX) (CIK 0001642380) (IMDX) — Dec 28, 2015
Oncocyte Corp (OCX) (CIK 0001642380)
Date: Dec. 28, 2015 · CIK: 0001642380 · Accession: 0001140361-15-045676
AI Filing Summary & Sentiment
File numbers found in text: 001-37648
Letter
Office of Healthcare and Insurance Securities and Exchange Commission Re: OncoCyte Corporation Form 10-12B File No. 001-37648
Dear Ms. Hayes:
This letter is being submitted on behalf of OncoCyte Corporation to confirm that, in accordance with discussions between OncoCyte and the staff, the definitive Information Statement that will be mailed to BioTime shareholders will include the following revisions from the Preliminary Information Statement contained in Amendment No 1 to the Form 10: (a) in the financial statements, line items that are presently labeled “available for sale securities” will instead be labeled “BioTime shares held as available for sale securities;” and (b) on page 82 the residual reference to Excluded Jurisdictions will be deleted.
OncoCyte will also be submitting today a request to have the Form 10 declared effective on Wednesday, December 30, 2015.
Please direct all correspondence and communications with respect to the Form 10 to the undersigned.
Very truly yours,
/s/Richard S. Soroko
Show Raw Text
CORRESP 1 filename1.htm LAW OFFICES Thompson, Welch, Soroko & Gilbert llp 3950 CIVIC CENTER DRIVE, SUITE 300 SAN RAFAEL, CA 94903 (415) 448-5000 FACSIMILE RICHARD S. SOROKO (415) 448-5010 email: rsoroko@TWSGLAW.com SAN FRANCISCO OFFICE (415) 262-1200 December 28, 2015 Suzanne Hayes Assistant Director Office of Healthcare and Insurance Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: OncoCyte Corporation Form 10-12B File No. 001-37648 Dear Ms. Hayes: This letter is being submitted on behalf of OncoCyte Corporation to confirm that, in accordance with discussions between OncoCyte and the staff, the definitive Information Statement that will be mailed to BioTime shareholders will include the following revisions from the Preliminary Information Statement contained in Amendment No 1 to the Form 10: (a) in the financial statements, line items that are presently labeled “available for sale securities” will instead be labeled “BioTime shares held as available for sale securities;” and (b) on page 82 the residual reference to Excluded Jurisdictions will be deleted. OncoCyte will also be submitting today a request to have the Form 10 declared effective on Wednesday, December 30, 2015. Please direct all correspondence and communications with respect to the Form 10 to the undersigned. Very truly yours, /s/Richard S. Soroko Richard S. Soroko